US20040067245A1 - Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin - Google Patents

Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin Download PDF

Info

Publication number
US20040067245A1
US20040067245A1 US10/436,310 US43631003A US2004067245A1 US 20040067245 A1 US20040067245 A1 US 20040067245A1 US 43631003 A US43631003 A US 43631003A US 2004067245 A1 US2004067245 A1 US 2004067245A1
Authority
US
United States
Prior art keywords
skin
acid
aging
improvement
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/436,310
Other languages
English (en)
Inventor
Harish Mahalingam
Christos Kyrou
Michael Traudt
Dmitri Ptchelintsev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/741,383 external-priority patent/US6562321B2/en
Application filed by Avon Products Inc filed Critical Avon Products Inc
Priority to US10/436,310 priority Critical patent/US20040067245A1/en
Assigned to AVON PRODUCTS, INC. reassignment AVON PRODUCTS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PTCHELINTSEV, DMITRI, TRAUDT, MICHAEL, KYROU, CHRISTOS D., MAHALINGAM, HARISH
Publication of US20040067245A1 publication Critical patent/US20040067245A1/en
Priority to MXPA04008328 priority patent/MX282977B/es
Priority to DE602004032018T priority patent/DE602004032018D1/de
Priority to CA2477748A priority patent/CA2477748C/en
Priority to EP04760943A priority patent/EP1622579B1/en
Priority to PL04760943T priority patent/PL1622579T3/pl
Priority to EP11160243A priority patent/EP2409681A1/en
Priority to PCT/US2004/014468 priority patent/WO2004100889A2/en
Priority to CNA2004800001282A priority patent/CN1697645A/zh
Priority to AT04760943T priority patent/ATE503454T1/de
Priority to AU2004238316A priority patent/AU2004238316B2/en
Priority to BRPI0403036-2A priority patent/BRPI0403036B1/pt
Priority to JP2005518232A priority patent/JP2006514997A/ja
Priority to TW093113081A priority patent/TWI280139B/zh
Priority to JP2008261918A priority patent/JP2009046510A/ja
Priority to US13/584,136 priority patent/US8808765B2/en
Priority to US14/319,661 priority patent/US20140308376A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to compositions useful in treating hyperpigmentation and the various signs of dermatological aging in human skin.
  • the present invention also relates to cosmetic compositions and methods of using such compositions that improve the aesthetic appearance of skin.
  • the present invention relates to methods of applying the compositions to the skin to effect treatment and to improve the aesthetic appearance of skin, particularly, by providing anti-aging benefits to the skin.
  • Human skin color is determined primarily by the content of the pigment melanin in the basal epidermis layer.
  • Melanin is synthesized by the process of melanogenesis within melanocytes (pigment-producing cells). Melanin is deposited onto melanosomes, which are transferred to keratinocytes in the basal epidermal layer. Melanosomes present in these basal keratinocytes are the key determinants of skin color.
  • the keratinocytes leave the basal layer and undergo differentiation forming the cornified top layer of the skin. Once the keratinocytes leave the basal layer, the melanosomes lose their characteristic electron dense structure, and the load of melanin is carried to the surface of the skin by the differentiating keratinocytes.
  • the skin can become hyperpigmented when too much melanin concentrates at one area or portion of the skin due to the retention time of the melanosomes in the basal layer. Hyperpigmentation can also occur as a result of overexposure to the sun or other inflammatory stimuli. Hyperpigmentation can take the form of solar lentigines (age spots), ephilides (freckles), melasma, chloasma, and pigmented keratoses.
  • the prior art discloses ways to treat hyperpigmentation by application of skin lightening agents.
  • Representative skin lightening agents include hydroquinone and Vitamin C. Such agents typically lighten the skin by inhibiting the expression of tyrosinase enzymes involved in melanogenesis.
  • Such anti-aging active ingredients include, for example, a-hydroxy acids (e.g., lactic, glycolic, citric), b-hydroxy acids (e.g., salicylic; 5-n-octanoylsalicylic acids) and retinoids (retinoic acids; retinol). It is known that these anti-aging active ingredients have a significant disadvantage in that they frequently are associated with consumer discomfort characterized by burning, smarting, itching or sensation of tightness after application. There remains a general need in the cosmetics industry for products that retard or counter aging effects on the skin, and more specifically for products that produce such effects without undesirable side effects.
  • a-hydroxy acids e.g., lactic, glycolic, citric
  • b-hydroxy acids e.g., salicylic; 5-n-octanoylsalicylic acids
  • retinoids retinoic acids
  • a method and composition that comprises (a) a de-pigmenting agent or anti-aging agent in an amount effective to prevent, treat and/or ameliorate pigmentation or the various signs of aging at an area of skin to which it is applied, and (b) a cosmetically or pharmaceutically acceptable vehicle.
  • Suitable de-pigmenting agents include 3,3′-thiodipropionic acid, thiazolidine-2-carboxylic acid, Kaempferol-7-glucoside, perilla oil, and clofibrate and clofibrate analogs and/or derivatives, as well as those set forth below.
  • Suitable antiaging agents include 3,3′-thiodipropionic acid and/or its derivatives.
  • the present invention provides for de-pigmenting compositions containing an effective amount of one or more depigmenting agents which, when applied to human skin, prevent, treat and/or ameliorate pigmentation at the area or portion of skin to which they are applied.
  • the compositions are effective at reducing or diminishing pigmented areas or portions of the skin such as age spots, freckles, melasma, chloasma, and pigmented keratoses.
  • the compositions are topically applied to the skin.
  • the present invention also provides for anti-aging compositions containing an effective amount of one or more ingredients which, when applied to human skin, prevent, treat and/or ameliorate the various signs of aging at the area or portion of skin to which they are applied.
  • the present invention provides anti-aging benefits to and improves the aesthetic appearance of the skin.
  • the present invention provides compositions and methods for treating skin to prevent, inhibit, reduce and/or ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • Such signs of aging include, but are not limited to skin fragility; loss of collagen and/or elastin; estrogen imbalance in skin; skin atrophy; appearance and/or depth of lines and/or wrinkles, including fine lines; skin discoloration, including dark eye circles; skin sagging; skin fatigue and/or stress, e.g. skin breakout due to environmental stress, such as pollution and/or temperature changes; skin dryness; skin flakiness; cellular aging; loss of skin tone, elasticity and/or luster; loss of skin firmness; poor skin texture; loss of skin elasticity and/or resiliency; and thin skin.
  • the benefits and improvements to the aesthetic appearance of skin can be manifested in any of the following: reduction in pore size; improvement in skin tone, radiance, clarity and/or tautness; promotion of anti-oxidant activity; improvement in skin firmness, plumpness, suppleness, and/or softness; improvement in procollagen and/or collagen production; improvement in skin texture and/or promotion of retexturization; improvement in skin barrier repair and/or function; improvement in appearance of skin contours; restoration of skin luster and/or brightness; replenishment of essential nutrients and/or constituents in the skin decreased by aging and/or menopause; improvement in communication among skin cells; increase in cell proliferation and/or multiplication; increase in skin cell metabolism decreased by aging and/or menopause; improvement in skin moisturization; promotion and/or acceleration of cell turnover; enhancement of skin thickness; increase in skin elasticity and/or resiliency; and enhancement of exfoliation, with or without the use of alpha or beta hydroxy acids, keto acids or other exfoliants.
  • a first embodiment of the present composition has a compound corresponding to the following Formula (I):
  • R 1 and R 2 are independently selected from the group of substituents consisting of hydrogen; alkyls, substituted or unsubstituted, branched or linear; alkenyls, substituted or unsubstituted, branched or linear, and having up to 5 double bonds; alkynyls, substituted or unsubstituted, branched or linear and having up to 5 triple bonds; aryls, substituted or unsubstituted; cycloalkyls, substituted and unsubstituted; and cycloalkenyls, substituted and unsubstituted.
  • Formula I compounds shall be referred to herein as either “de-pigmenting agents” or “anti-aging agents”.
  • the Formula I compound is 3,3′-thiodipropionic acid, wherein R 1 and R 2 are hydrogen.
  • a second embodiment of the present composition has a de-pigmenting agent corresponding to formula II:
  • R 3 and R 4 are defined the same as R 1 and R 2 in formula (I) above; in addition, R 3 can be an acyl group; wherein “n” is an integer from 1 to 4, preferably 1 to 3, and most preferably 1 to 2.
  • the de-pigmenting agent is perilla oil.
  • Perilla oil is derived from the seeds of the mint of the genus Perilla.
  • the de-pigmenting agent is clofibrate or a clofibrate analog or derivative.
  • Clofibrate is ethyl 2-(p-chlorophenoxy)isobutyrate, which corresponds to the following formula (IV):
  • a fifth embodiment of the present composition has a de-pigmenting agent corresponding to the following formula (III):
  • R 5 , R 6 , and R 7 are as defined as for R 1 and R 2 in formula (I) above.
  • the de-pigmenting agent of Formula III is kaempferol-7-glycoside wherein R 5 , R 6 and R 7 are hydrogen.
  • Kaempferol-7-glycoside is believed to reduce pigmentation by inhibiting tyrosinase but may also reduce pigmentation by alternate pathways.
  • the de-pigmenting agent is a combination of one or more of the above de-pigmenting agents.
  • the combination includes de-pigmenting agents that utilize different mechanisms of action.
  • a preferred combination includes kaempferol-7-glucoside and perilla oil or clofibrate (or a clofibrate analog or derivative).
  • the de-pigmenting agent is present in the composition at an amount effect to prevent, treat, or ameliorate pigmentation at the area or portion of skin to which it is applied.
  • the de-pigmenting agent is preferably present at about 0.0001 percentage by weight (wt %) to about 98 wt %, more preferably at about 0.001 wt % to about 30 wt %, and most preferably at about 0.05 wt % to about 10 wt % based on the total weight of the composition.
  • the composition is preferably applied to an affective area of skin for a period of time prevent, treat, or ameliorate pigmentation of the area of skin to which the composition is applied.
  • the amount of times per day and the period of time that the composition is to be applied to be effective will vary according to the percentage of active used in the composition, the additional ingredients in the composition (e.g., whether or not there is a penetration enhancer or additional depigmenting agents), as well as other factors known by those skilled in the art.
  • the anti-aging agent is present in the composition at an amount effect to prevent, treat, or ameliorate the various signs of aging in the area or portion of skin to which it is applied.
  • the anti-aging agent is preferably present at about 0.0001 percentage by weight (wt %) to about 98 wt %, more preferably at about 0.001 wt % to about 30 wt %, and most preferably at about 0.05 wt % to about 10 wt % based on the total weight of the composition.
  • the composition is preferably applied to an affective area of skin for a period of time to improve the aesthetic appearance of the area of skin to which the composition is applied.
  • the amount of times per day and the period of time that the composition is to be applied to be effective will vary according to the percentage of active used in the composition, the additional ingredients in the composition (e.g., whether or not there is a penetration enhancer or additional anti-agents), the targeted improvement as well as other factors known by those skilled in the art.
  • the present invention provides compositions and methods for treating skin to prevent, inhibit, reduce and/or ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • signs of aging include, but are not limited to skin fragility; loss of collagen and/or elastin; estrogen imbalance in skin; skin atrophy; appearance and/or depth of lines and/or wrinkles, including fine lines; skin discoloration, including dark eye circles; skin sagging; skin fatigue and/or stress, e.g.
  • the benefits and improvements to the aesthetic appearance of skin can be manifested in any of the following: reduction in pore size; improvement in skin tone, radiance, clarity and/or tautness; promotion of anti-oxidant activity; improvement in skin firmness, plumpness, suppleness, and/or softness; improvement in procollagen and/or collagen production; improvement in skin texture and/or promotion of retexturization; improvement in skin barrier repair and/or function; improvement in appearance of skin contours; restoration of skin luster and/or brightness; replenishment of essential nutrients and/or constituents in the skin decreased by aging and/or menopause; improvement in communication among skin cells; increase in cell proliferation and/or multiplication; increase in skin cell metabolism decreased by aging and/or menopause; improvement in skin moisturization; promotion and/or acceleration of cell turnover; enhancement of skin thickness; increase in skin elasticity and/or resiliency; and enhancement of exfoliation, with or without the use of alpha or beta hydroxy acids, keto acids or other exfoliants.
  • compositions on are preferably used in methods of improving, ameliorating or treating the following signs of aging skin: texture, clarity, pigmentation (mottled and/or discrete), fine wrinkles, coarse wrinkles, sallowness, laxness, sagging, turgor, undereye puffiness, and/or overall photodamage.
  • the Formula I compound is 3,3′-thiodipropionic acid and/or a derivative thereof.
  • the Formula I compound is 3,3′-thiodipropionic acid.
  • compositions of the present invention comprise a pharmaceutically and/or cosmetically acceptable vehicle to provide bulk and physical form.
  • vehicle is hypoallergenic, as allergens and other irritating agents exacerbate pigmentation.
  • Suitable vehicles include, but are not limited to, cetyl alcohol, ethanol, glycerin, myristyl palmitate, polyvinyl alcohol, propylene glycol, propanol, and water, and mixtures thereof.
  • the depigmenting/anti-aging agent is admixed with the vehicle(s) along with any other adjuvants or ingredients to form the topical composition.
  • the compositions of the present invention may also include actives in the form of liposomes.
  • the present composition may take any suitable form such as a solution, cream, serum, stick, patch, mask, towelette, lotion, emulsion, ointment or gel.
  • the present composition may optionally have one or more of the following ingredients: anesthetics, antiallergenics, antimicrobial agents, antiseptics, chelating agents, colorants, demulcents, emollients, emulsifiers, exfolients, fragrances, humectants, lubricants, moisturizers, preservatives, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, and mixtures thereof.
  • anesthetics antiallergenics, antimicrobial agents, antiseptics, chelating agents, colorants, demulcents, emollients, emulsifiers, exfolients, fragrances, humectants, lubricants, moisturizers, preservatives, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, and mixtures thereof.
  • the present invention may also include conventional cosmetic acitive agents, such as other conventional hypopigmenting agents, such as hydroquinone, ascorbic acid (Vitamin C) and/or licorice extract; retinoids, such as retinol or retinoic acid; antiinflammatory agents, such as bisabolol, anti-acne agents, such as salicylic acid; exfoliants, such as alpha-hydroxy acids, beta-hydroxy acids, keto acids, oxa acids or oxa diacids (disclosed in U.S. Pat. Nos. 5,847,003 and 5,834,513); ascorbyl-phosphoryl-cholesterol (disclosed in U.S. Pat. No.
  • sunscreens such as oxybenzone, octyl methoxycinnamate, octyl salicylate, octocrylene, titanium dioxide, zinc oxide, butyl methoxydibenzoylmethane, methylene bis-benzotriazoylteramehtylbuthylphenol (MBBT), bis-ethylhexyl oxyphenol methoxyphenol triazine (BEMT); or anti-aging agents; or any combination thereof.
  • MBT methylene bis-benzotriazoylteramehtylbuthylphenol
  • BEMT bis-ethylhexyl oxyphenol methoxyphenol triazine
  • anti-aging agents or any combination thereof.
  • Preferred alpha-hydroxy acids include lactic acid, glycolic acid, or a mixture thereof.
  • the preferred oxa diacid is 3,6,9-trioxaundecanedioic acid.
  • Formula I compounds may be used to enhance the effectiveness of other skin care actives, such as those disclosed above and those skin care actives disclosed in U.S. Pat. No. 6,492,326 at col. 5, lines 9 through col. 20, line 50, which is incorporated herein by reference.
  • Ingredient wt % De-pigmenting agent or anti-aging agent 0.001 to 98 e.g. (3,3′-thiodipropionic acid) pH adjusting agent (e.g. ammonium 0.001 to 4 Humectants (e.g. glycols, glycerols) 0.5 to 15 Thickeners (e.g. gums, starches polymers) 0.1 to 4 Chelating Agents (e.g. EDTA) 0.001 to 0.5 Emollients (e.g. isopropyl myristate, fatty esters) 1 to 10 Silicones (cyclomethicone-pentamer) 0.1 to 15 Preservative (e.g.
  • Alcohols e.g. ethanol
  • Antioxidants e.g. vitamin E acetate
  • Anti-inflammatory e.g. bisabolol
  • Sunscreen e.g. titanium dioxide/benzophenone-3, 0.01 to 15 Butyl methoxydibenzoylmethane
  • Water q.s.
  • the preferred anti-aging agent is 3,3′-thiodipropionic acid.
  • the cosmetic composition includes at least one ingredient selected from the group consisting of: palmatoyl tetrapeptide-3 (available under the trade name RIGIN from Sederma, France), Gymnostemma pentaphyllum and/or an extract therefrom, Stenolama chusana and/or an extract therefrom, Morinda citrifolia and/or an extract therefrom, Butea frondosa and/or an extract therefrom, Luteoline 7-beta-glucoside, Chlorosalicylic Acid, Naringi crenulata and/or an extract therefrom, Methylthioadenosine, Ferutinin, Ilex purpurea and

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
US10/436,310 2000-12-20 2003-05-12 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin Abandoned US20040067245A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US10/436,310 US20040067245A1 (en) 2000-12-20 2003-05-12 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
AU2004238316A AU2004238316B2 (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
BRPI0403036-2A BRPI0403036B1 (pt) 2003-05-12 2004-05-07 "método cosmético para melhorar os sinais de envelhecimento da pele"
DE602004032018T DE602004032018D1 (de) 2003-05-12 2004-05-07 Kosmetische zusammensetzungen und verfahren zu ihrscheinungsbilds der haut
EP11160243A EP2409681A1 (en) 2003-05-12 2004-05-07 Method for improving the aesthetic appearance of skin by enhancing the skin thickness
JP2005518232A JP2006514997A (ja) 2003-05-12 2004-05-07 皮膚の審美的外観を改善する化粧品組成物及びそれを使用する方法
CA2477748A CA2477748C (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
EP04760943A EP1622579B1 (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
PL04760943T PL1622579T3 (pl) 2003-05-12 2004-05-07 Kompozycje kosmetyczne i sposoby ich zastosowania do polepszania wyglądu estetycznego skóry
MXPA04008328 MX282977B (es) 2003-05-12 2004-05-07 Composiciones cosmeticas y metodos para usarlas para mejorar el aspecto estetico de la piel.
PCT/US2004/014468 WO2004100889A2 (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
CNA2004800001282A CN1697645A (zh) 2003-05-12 2004-05-07 改善皮肤的美观的化妆品组合物及其应用方法
AT04760943T ATE503454T1 (de) 2003-05-12 2004-05-07 Kosmetische zusammensetzungen und verfahren zu ihrer verwendung zur verbesserung des ästhetischen erscheinungsbilds der haut
TW093113081A TWI280139B (en) 2003-05-12 2004-05-10 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
JP2008261918A JP2009046510A (ja) 2003-05-12 2008-10-08 皮膚の審美的外観を改善する化粧品組成物及びそれを使用する方法
US13/584,136 US8808765B2 (en) 2003-05-12 2012-08-13 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US14/319,661 US20140308376A1 (en) 2000-12-20 2014-06-30 Cosmetic Compositions and Methods for Using Same to Improve the Aesthetic Appearance of Skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/741,383 US6562321B2 (en) 2000-12-20 2000-12-20 Compositions and methods for treating hyperpigmentation
US10/436,310 US20040067245A1 (en) 2000-12-20 2003-05-12 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/741,383 Continuation-In-Part US6562321B2 (en) 2000-12-20 2000-12-20 Compositions and methods for treating hyperpigmentation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/584,136 Continuation US8808765B2 (en) 2000-12-20 2012-08-13 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin

Publications (1)

Publication Number Publication Date
US20040067245A1 true US20040067245A1 (en) 2004-04-08

Family

ID=33449708

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/436,310 Abandoned US20040067245A1 (en) 2000-12-20 2003-05-12 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US13/584,136 Expired - Lifetime US8808765B2 (en) 2000-12-20 2012-08-13 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US14/319,661 Abandoned US20140308376A1 (en) 2000-12-20 2014-06-30 Cosmetic Compositions and Methods for Using Same to Improve the Aesthetic Appearance of Skin

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/584,136 Expired - Lifetime US8808765B2 (en) 2000-12-20 2012-08-13 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US14/319,661 Abandoned US20140308376A1 (en) 2000-12-20 2014-06-30 Cosmetic Compositions and Methods for Using Same to Improve the Aesthetic Appearance of Skin

Country Status (13)

Country Link
US (3) US20040067245A1 (pt)
EP (2) EP1622579B1 (pt)
JP (2) JP2006514997A (pt)
CN (1) CN1697645A (pt)
AT (1) ATE503454T1 (pt)
AU (1) AU2004238316B2 (pt)
BR (1) BRPI0403036B1 (pt)
CA (1) CA2477748C (pt)
DE (1) DE602004032018D1 (pt)
MX (1) MX282977B (pt)
PL (1) PL1622579T3 (pt)
TW (1) TWI280139B (pt)
WO (1) WO2004100889A2 (pt)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115146A1 (en) * 2002-12-17 2004-06-17 Avon Products, Inc. Use of active extracts to lighten skin, lips, hair and/or nails
US20050136028A1 (en) * 2003-12-19 2005-06-23 Dmitri Ptchelintsev Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
WO2006025307A1 (ja) * 2004-08-30 2006-03-09 Kao Corporation シワ改善剤、脂肪分解促進剤、皮膚外用組成物及び飲食物組成物
US20070292537A1 (en) * 2004-12-22 2007-12-20 Jones Brian C Method and composition for reducing appearance of wrinkles
US20080126129A1 (en) * 1981-12-10 2008-05-29 Manzo Roberto P Process for enhancing aesthetic or medical skin procedure
US20090092561A1 (en) * 2007-10-09 2009-04-09 Lupia Joseph A Body-care and household products and compositions comprising specific sulfur-containing compounds
US20110151029A1 (en) * 2009-12-22 2011-06-23 Avon Products, Inc. Paxillin Stimulating Compositions and Cosmetic Uses Thereof
US20130280187A1 (en) * 2012-04-20 2013-10-24 The Procter & Gamble Company Compositions and Methods for Improving the Appearance of Facial Pores
WO2014035401A1 (en) * 2012-08-30 2014-03-06 Avon Products, Inc. Dickkopf-1 expression modulating compositions and uses thereof
KR20150019681A (ko) * 2013-08-14 2015-02-25 주식회사 엘지생활건강 피부 재생, 주름개선, 항산화 및 항염증용 조성물
US9023327B2 (en) 2012-08-30 2015-05-05 Avon Products, Inc. DICKKOPF-1 expression modulating compositions and uses thereof
EP2964334A4 (en) * 2013-03-07 2016-10-12 Avon Prod Inc COMPOSITIONS AND METHODS FOR TREATMENT OF ABIRED HAIR

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2902324B1 (fr) * 2006-06-20 2009-04-03 Oreal Utilisation d'acide ellagique pour le traitement de la canitie
JPWO2008018133A1 (ja) * 2006-08-10 2009-12-24 株式会社ノエビア 保湿剤、細胞賦活剤、美白剤、中性脂肪蓄積抑制剤、抗酸化剤、及び皮膚外用剤
EP1902756A1 (en) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Composition and method for treating skin by administering silybin and piperine/terahydropiperine
EP1902755A1 (en) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Cosmetic compositions decreasing GM-CSF release induced by nickel salts
JP2011510908A (ja) * 2007-06-11 2011-04-07 シャネル パフュームズ ビューテ 皮膚の老化を抑制するためのｆｎ３ｋおよび／またはｆｎ３ｋｒｐの発現を刺激するための有効薬剤の使用
US20100159045A1 (en) * 2007-06-11 2010-06-24 Chanel Parfums Beaute Cosmetic use of active agents for stimulating the expression of fn3k and/or fn3k rp to improve the skin's barrier function
EP2365333B1 (en) 2007-10-01 2014-11-26 The University Of British Columbia Granzyme A diagnostics
EP2205278A4 (en) 2007-10-01 2011-11-16 Univ British Columbia TREATMENT OF DISSEQUISITION, ANEURISMA AND ATHEROSCLEROSIS WITH GRANZYM B-INHIBITORS
JP5425413B2 (ja) * 2008-05-26 2014-02-26 モリンダ インコーポレーテッド エラスターゼ阻害剤
US7994175B2 (en) * 2008-12-29 2011-08-09 Avon Products, Inc Cosmetic use of 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides and related compounds
US20110262505A1 (en) 2010-04-22 2011-10-27 Gina Athwal Seaweed-derived cosmetic compositions
CN106727054A (zh) * 2010-06-30 2017-05-31 雅芳产品公司 用于刺激magp‑1以改善皮肤外观的组合物和方法
WO2014163896A1 (en) * 2013-03-12 2014-10-09 Avon Products, Inc A topical lightening composition and methods of use thereof
EP3606653A1 (en) * 2017-04-03 2020-02-12 L'oreal System for forming a cosmetic composition and skin care management system
TW202015652A (zh) * 2018-05-16 2020-05-01 日商太田油脂股份有限公司 皮膚光老化預防劑、以及、含有該類物質的功能性化妝品
CN110200883A (zh) * 2019-06-19 2019-09-06 武汉百思凯瑞生物科技有限公司 一种抗敏共输送纳米组合物及其制备方法和应用

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780042A (en) * 1993-02-25 1998-07-14 Beiersdorf Ag Synergistic light protection combinations and cosmetic and dermatological formulations comprising such combinations
US6004543A (en) * 1995-12-22 1999-12-21 L'oreal L-2-oxothiazolidine-4-carboxylic acid derivatives and use thereof for skincare
US6068848A (en) * 1997-12-17 2000-05-30 Color Access, Inc. Antioxidant mixture comprising tocopherol
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6121243A (en) * 1994-12-13 2000-09-19 Beiersdorf Ag Treatment of skin with a formulation comprising alpha-glucosyl rutin and one or more cinnamic acid derivatives
US6203802B1 (en) * 1990-03-16 2001-03-20 L'oreal Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6313085B1 (en) * 1999-06-29 2001-11-06 Cognis Deutschland Gmbh High-concentration flowable anionic surfactant mixtures containing alkyl ether sulfates and alkyl sulfates
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20020141953A1 (en) * 2000-12-20 2002-10-03 Avon Products, Inc Compositions and methods for treating hyperpigmentation
US6486147B2 (en) * 2000-04-10 2002-11-26 L'oreal Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof
US6500857B1 (en) * 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
US20030068349A1 (en) * 2001-07-04 2003-04-10 Axel Jentzsch Use of 5'-deoxy-5'-methylthioadenosine in skin cosmetic compositions
US20030198657A1 (en) * 2000-03-21 2003-10-23 Avon Products, Inc. Methods using phytol to improve the appearance of skin and compositions for such methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686489A (en) * 1986-12-23 1997-11-11 Tristrata Technology, Inc. Alpha hydroxyacid esters for skin aging
BE1000724A6 (fr) * 1987-05-20 1989-03-21 Stiefel Lab Ltd Compositions a base de dithranol.
CH686285A5 (fr) * 1992-08-06 1996-02-29 Beiersdorf Ag Preparation cosmetique ou pharmaceutique servant a retarder le vieillissement de la peau humaine.
US5866147A (en) 1995-05-15 1999-02-02 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
US5834513A (en) * 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions
US5847003A (en) 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
JP3636973B2 (ja) * 2000-06-26 2005-04-06 株式会社カネボウ化粧品 ラジカル消去剤および化粧料
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203802B1 (en) * 1990-03-16 2001-03-20 L'oreal Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process
US5780042A (en) * 1993-02-25 1998-07-14 Beiersdorf Ag Synergistic light protection combinations and cosmetic and dermatological formulations comprising such combinations
US6121243A (en) * 1994-12-13 2000-09-19 Beiersdorf Ag Treatment of skin with a formulation comprising alpha-glucosyl rutin and one or more cinnamic acid derivatives
US6004543A (en) * 1995-12-22 1999-12-21 L'oreal L-2-oxothiazolidine-4-carboxylic acid derivatives and use thereof for skincare
US6068848A (en) * 1997-12-17 2000-05-30 Color Access, Inc. Antioxidant mixture comprising tocopherol
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6313085B1 (en) * 1999-06-29 2001-11-06 Cognis Deutschland Gmbh High-concentration flowable anionic surfactant mixtures containing alkyl ether sulfates and alkyl sulfates
US20030198657A1 (en) * 2000-03-21 2003-10-23 Avon Products, Inc. Methods using phytol to improve the appearance of skin and compositions for such methods
US6486147B2 (en) * 2000-04-10 2002-11-26 L'oreal Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof
US20020141953A1 (en) * 2000-12-20 2002-10-03 Avon Products, Inc Compositions and methods for treating hyperpigmentation
US6562321B2 (en) * 2000-12-20 2003-05-13 Avon Products, Inc. Compositions and methods for treating hyperpigmentation
US20030068349A1 (en) * 2001-07-04 2003-04-10 Axel Jentzsch Use of 5'-deoxy-5'-methylthioadenosine in skin cosmetic compositions
US6500857B1 (en) * 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080126129A1 (en) * 1981-12-10 2008-05-29 Manzo Roberto P Process for enhancing aesthetic or medical skin procedure
US20060013782A1 (en) * 2002-12-17 2006-01-19 Avon Products, Inc. Use of active extracts to improve the appearance of skin, lips, hair and/or nails
US7189419B2 (en) * 2002-12-17 2007-03-13 Avon Products, Inc. Use of active extracts to lighten skin, lips, hair, and/or nails
AU2003297126B2 (en) * 2002-12-17 2007-04-19 Avon Products, Inc. Use of active extracts to improve the appearance of skin, lips, hair and/or nails
US20040115146A1 (en) * 2002-12-17 2004-06-17 Avon Products, Inc. Use of active extracts to lighten skin, lips, hair and/or nails
US20050136028A1 (en) * 2003-12-19 2005-06-23 Dmitri Ptchelintsev Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
US7842316B2 (en) 2003-12-19 2010-11-30 Avon Products, Inc. Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
US20070264364A1 (en) * 2003-12-19 2007-11-15 Avon Products, Inc. Cosmetic compositions having extracts of amomum melegueta and methods of treating skin
JP2010227098A (ja) * 2004-08-30 2010-10-14 Kao Corp シワ改善剤、脂肪分解促進剤、皮膚外用組成物及び飲食物組成物
US8445005B2 (en) 2004-08-30 2013-05-21 Kao Corporation Antiwrinkle agent, lipolysis promoter, external composition for skin and food and beverage composition
KR100882618B1 (ko) * 2004-08-30 2009-02-06 카오 가부시키가이샤 지방 분해 촉진제 및 피부외용 조성물
US20090149550A1 (en) * 2004-08-30 2009-06-11 Kao Corporation Wrinkle reduction agent, lipolysis accelerator, composition for external use on skin, and food or beverage composition
US20070259057A1 (en) * 2004-08-30 2007-11-08 Kao Corporation Wrinkle Reduction Agent, Lipolysis Accelerator, Composition for External Use on Skin, and Food or Beverage Composition
WO2006025307A1 (ja) * 2004-08-30 2006-03-09 Kao Corporation シワ改善剤、脂肪分解促進剤、皮膚外用組成物及び飲食物組成物
JP4673851B2 (ja) * 2004-08-30 2011-04-20 花王株式会社 脂肪分解促進剤及び痩身用皮膚外用組成物
JPWO2006025307A1 (ja) * 2004-08-30 2008-05-08 花王株式会社 シワ改善剤、脂肪分解促進剤、皮膚外用組成物及び飲食物組成物
US20070292537A1 (en) * 2004-12-22 2007-12-20 Jones Brian C Method and composition for reducing appearance of wrinkles
US9149665B2 (en) 2004-12-22 2015-10-06 Avon Products, Inc. Method and composition for reducing appearance of wrinkles
EP1827111A4 (en) * 2004-12-22 2015-07-22 Avon Prod Inc METHOD AND COMPOSITION FOR REDUCING THE APPEARANCE OF WRINKLES
US20090092561A1 (en) * 2007-10-09 2009-04-09 Lupia Joseph A Body-care and household products and compositions comprising specific sulfur-containing compounds
US8394427B2 (en) 2009-12-22 2013-03-12 Avon Products, Inc. Paxillin stimulating compositions and cosmetic uses thereof
US9066896B2 (en) 2009-12-22 2015-06-30 Avon Products, Inc. Paxillin stimulating compositions and cosmetic uses thereof
WO2011087654A1 (en) * 2009-12-22 2011-07-21 Avon Products, Inc. Paxillin stimulating compositions and cosmetic uses thereof
US20110151029A1 (en) * 2009-12-22 2011-06-23 Avon Products, Inc. Paxillin Stimulating Compositions and Cosmetic Uses Thereof
US20130280187A1 (en) * 2012-04-20 2013-10-24 The Procter & Gamble Company Compositions and Methods for Improving the Appearance of Facial Pores
WO2014035401A1 (en) * 2012-08-30 2014-03-06 Avon Products, Inc. Dickkopf-1 expression modulating compositions and uses thereof
US9023327B2 (en) 2012-08-30 2015-05-05 Avon Products, Inc. DICKKOPF-1 expression modulating compositions and uses thereof
EP2964334A4 (en) * 2013-03-07 2016-10-12 Avon Prod Inc COMPOSITIONS AND METHODS FOR TREATMENT OF ABIRED HAIR
US10874598B2 (en) 2013-03-07 2020-12-29 Avon Products, Inc. Compositions and methods for treating damaged hair
KR20150019681A (ko) * 2013-08-14 2015-02-25 주식회사 엘지생활건강 피부 재생, 주름개선, 항산화 및 항염증용 조성물
KR102020817B1 (ko) 2013-08-14 2019-09-11 주식회사 엘지생활건강 피부 재생, 주름개선, 항산화 및 항염증용 조성물

Also Published As

Publication number Publication date
EP2409681A1 (en) 2012-01-25
TW200505490A (en) 2005-02-16
MXPA04008328A (es) 2005-02-03
CA2477748C (en) 2011-12-06
EP1622579A2 (en) 2006-02-08
JP2006514997A (ja) 2006-05-18
EP1622579B1 (en) 2011-03-30
WO2004100889A2 (en) 2004-11-25
CN1697645A (zh) 2005-11-16
BRPI0403036B1 (pt) 2014-12-16
CA2477748A1 (en) 2004-11-12
AU2004238316B9 (en) 2007-08-23
TWI280139B (en) 2007-05-01
AU2004238316B2 (en) 2007-08-23
JP2009046510A (ja) 2009-03-05
ATE503454T1 (de) 2011-04-15
WO2004100889A3 (en) 2005-03-24
US20140308376A1 (en) 2014-10-16
US20120315344A1 (en) 2012-12-13
BRPI0403036A (pt) 2005-11-22
DE602004032018D1 (de) 2011-05-12
US8808765B2 (en) 2014-08-19
EP1622579A4 (en) 2007-12-12
PL1622579T3 (pl) 2011-08-31
AU2004238316A1 (en) 2004-11-25
MX282977B (es) 2011-01-17

Similar Documents

Publication Publication Date Title
US8808765B2 (en) Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US6562321B2 (en) Compositions and methods for treating hyperpigmentation
EP1441686B1 (en) Topical cosmetic composition with skin rejuvenation benefits
US20030118617A1 (en) Resveratrol analogues
EP1536763B1 (en) Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent
WO2006068778A2 (en) The use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products
JP4335152B2 (ja) 皮膚、唇、毛髪および／または爪の外観を改善するための活性エキスの使用
US20070238764A1 (en) Use of Sphingoid Base Associated with Nicotinic Acid or a Nicotinic Acid Amide in the Form of Depigmentation Agent
US9592186B2 (en) Topical compositions and methods for skin lightening
CN109996530B (zh) 皱纹改善剂
KR102623565B1 (ko) 베타피넨을 유효성분으로 포함하는 피부 개선용 조성물
US20230346678A1 (en) Topical compositions containing vitamin c
EP3200752A1 (en) Topical compositions and methods for skin lightening

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVON PRODUCTS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHALINGAM, HARISH;KYROU, CHRISTOS D.;TRAUDT, MICHAEL;AND OTHERS;REEL/FRAME:014568/0018;SIGNING DATES FROM 20030903 TO 20030912

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION